Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expects To Review Half Of All Generic Drugs By Six-Month Goal In 2001

Executive Summary

FDA projects it will be able to review 50% of generic drug applications within six months in FY 2001.

You may also be interested in...



CBER Retooling Application Database: Could Improve Post Approval Tracking

The Center for Biologics Evaluation & Research is implementing a new application database that is expected to improve its ability to keep track of post-marketing commitments and changes to applications.

OGD Hopes To Reach 315 ANDA Approvals In 2000, Up 30% Over Slow 1999

FDA's Office of Generic Drugs estimates it could approve or tentatively approve 315 generic drug applications in calendar year 2000, a 30% increase from 1999.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS037013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel